MELAS stands for mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes. It is a rare genetic disorder caused by mutations in mitochondrial DNA that prevent cells from producing energy normally. The condition primarily affects the brain, muscles, and nervous system, and symptoms most often appear in childhood or young adulthood.
How MELAS Affects the Body
Every cell in your body contains mitochondria, small structures that convert food into usable energy. In MELAS, a genetic mutation disrupts this energy production process. Cells that demand the most energy, particularly those in the brain and muscles, are hit hardest. When mitochondria can’t keep up with energy demands, cells switch to less efficient backup pathways that produce lactic acid as a byproduct. This acid builds up in the blood and tissues, a state called lactic acidosis, which contributes to many of the condition’s symptoms.
Early Symptoms
The first signs of MELAS often appear between ages 2 and 40, though childhood onset is most common. Early symptoms can seem nonspecific: muscle weakness, muscle pain, recurrent headaches, loss of appetite, vomiting, and seizures. Many children with MELAS also have short stature. Because these symptoms overlap with many other conditions, MELAS is frequently misdiagnosed or diagnosed late.
Lactic acidosis itself causes fatigue, abdominal pain, muscle weakness, vomiting, and difficulty breathing. These symptoms can flare during illness, exercise, or periods of fasting, all of which push mitochondria to work harder than they’re able to.
Stroke-Like Episodes
The hallmark of MELAS is recurrent stroke-like episodes. These look similar to a traditional stroke, with sudden weakness on one side of the body, vision changes, altered consciousness, severe migraine-like headaches, and seizures. But they differ from typical strokes in important ways.
A standard ischemic stroke happens when a blood vessel in the brain is blocked by a clot. In MELAS, brain imaging consistently shows no large vessel blockage. Instead, the affected brain tissue often shows signs of increased blood flow, the opposite of what happens during a clot-caused stroke. The damage spreads gradually over days to two weeks rather than appearing all at once, and it follows distinctive patterns that don’t match the territory of any single blood vessel. Researchers have identified a characteristic “horseshoe sign” on brain imaging that appears specific to MELAS when the damage reaches the parietal cortex.
These episodes tend to affect the back and sides of the brain most frequently, which explains why vision problems, including partial or complete vision loss, are so common. Repeated episodes cause progressive brain damage that can lead to permanent vision loss, movement difficulties, and dementia. In one large study, neurological causes including dementia, seizures, and stroke accounted for 45% of deaths in MELAS patients.
Other Organs Affected
Because mitochondria exist in virtually every cell, MELAS can affect organs beyond the brain and muscles. Hearing loss is common. Heart problems, kidney disease, diabetes, and hormonal imbalances all occur at higher rates. Some people experience gastrointestinal issues, including difficulty moving food through the digestive tract. Involuntary muscle spasms and impaired coordination can also develop over time.
Genetic Cause and Inheritance
MELAS is caused by mutations in mitochondrial DNA, which you inherit exclusively from your mother. The most common mutation is a single letter change in a gene called MTTL1 (the m.3243A>G mutation), found in roughly 80% of cases. Mutations in several other mitochondrial genes can also cause MELAS, though these are far less common.
One key concept in mitochondrial disease is heteroplasmy. Each cell contains hundreds or thousands of copies of mitochondrial DNA, and in someone with MELAS, only a fraction of those copies may carry the mutation. The ratio of mutant to normal copies varies from cell to cell and from organ to organ. Generally, a higher percentage of mutant DNA leads to more severe disease, but this relationship is far from straightforward. Some people with high mutation levels remain relatively healthy, while others with lower levels develop serious symptoms. Factors beyond the mutation percentage itself, including how many total copies of mitochondrial DNA a cell maintains, appear to influence severity.
Because the mutation passes through the maternal line, a mother who carries it will pass it to all her children. However, each child may inherit a different proportion of mutant versus normal mitochondrial DNA, which is why siblings can be affected very differently.
How MELAS Is Diagnosed
Diagnosis typically involves a combination of clinical evaluation, blood tests, brain imaging, and genetic testing. Elevated lactic acid levels in the blood are a key early clue. In one study, patients with mitochondrial disease affecting the brain had blood lactate levels roughly three times higher than those without mitochondrial disease. Measuring lactate in spinal fluid can be even more informative: levels above about 20 mg/dL in spinal fluid were highly accurate at identifying mitochondrial disease affecting the central nervous system.
Brain MRI reveals stroke-like lesions in approximately 90% of MELAS patients. A specialized MRI technique called magnetic resonance spectroscopy can detect elevated lactate peaks directly within brain tissue, providing further evidence. Importantly, MRI patterns can help distinguish MELAS from a true ischemic stroke, since the type of brain swelling and its distribution differ between the two conditions.
Muscle biopsy, while less commonly needed today thanks to genetic testing, can reveal a characteristic finding called ragged red fibers. These represent clusters of abnormal mitochondria accumulating beneath the surface of muscle cells, essentially the cell’s failed attempt to compensate for poor energy production by making more (dysfunctional) mitochondria. Genetic testing of blood or muscle tissue for the m.3243A>G mutation and other known variants confirms the diagnosis.
Treatment and Management
There is no cure for MELAS, and treatment focuses on managing symptoms, reducing the frequency of stroke-like episodes, and supporting cellular energy production.
L-arginine is one of the most studied treatments. It works by boosting production of nitric oxide, a molecule that relaxes blood vessels and improves blood flow. During an acute stroke-like episode, it can be given intravenously. For ongoing prevention, it’s taken orally in divided doses throughout the day. Long-term data suggest that regular use may improve survival and reduce disability from stroke-like episodes compared to the expected disease course. L-citrulline, a related compound that the body converts into arginine, is sometimes used for patients who continue to have episodes despite arginine therapy.
High-dose taurine has shown enough promise in clinical studies that it received regulatory approval in Japan for reducing stroke-like episodes in MELAS, though it has not been approved for this use in the United States. Taurine appears to help maintain the chemical balance mitochondria need to function and may correct a specific molecular defect caused by the m.3243A>G mutation.
Most patients also take a combination of supplements aimed at supporting whatever mitochondrial function remains. This “mitochondrial cocktail” commonly includes coenzyme Q10 (a molecule central to the energy production chain that also acts as an antioxidant), riboflavin (vitamin B2, which supports the assembly of key components of the energy production machinery), and a general multivitamin. The specific combination is tailored to each person’s genetic variant and symptoms.
Beyond supplements, management includes controlling seizures with appropriate medications, monitoring for diabetes and heart disease, and addressing hearing loss. Avoiding known triggers for metabolic crises, such as prolonged fasting, extreme physical exertion, and certain medications that stress mitochondria, is an important part of daily life with MELAS.
Long-Term Outlook
The prognosis for MELAS varies widely depending on when symptoms begin and how severe the stroke-like episodes are. In a large retrospective study, 50% of patients with standard-onset MELAS had died within 25 years of their first symptoms, with the average age at death around 28 years for those with childhood or young adult onset. Patients who developed symptoms later in life had significantly later ages at death (averaging around 61 years), though the time from symptom onset to death was similar in both groups.
Dementia was the leading cause of death overall, reflecting the cumulative brain damage from repeated stroke-like episodes. Seizures, heart failure, kidney failure, and bowel complications were also significant causes. Seizures were particularly common in MELAS, affecting nearly 90% of patients diagnosed with the full syndrome, compared to only about 17% of those with the same genetic mutation but a milder presentation.
The progressive nature of the disease means that management goals often shift over time, from preventing stroke-like episodes early on to addressing accumulated neurological damage, organ complications, and quality of life as the disease advances.